Open Label Phase I Clinical Trial of Crotoxin in Patients With Advanced Cancer Using an Intravenous Route of Administration
Latest Information Update: 19 Jan 2024
Price :
$35 *
At a glance
- Drugs Crotoxin (Primary)
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Glioblastoma; Non-small cell lung cancer; Prostate cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Celtic Biotech
- 05 Sep 2023 Planned number of patients changed from 18 to 24.
- 05 Sep 2023 Planned End Date changed from 1 Feb 2019 to 1 Dec 2025.
- 05 Sep 2023 Planned primary completion date changed from 1 Oct 2018 to 1 Aug 2025.